Compound pharmaceutical composition for treating skin inflammatory diseases

Abstract

The disclosure relates to the field of pharmaceutical technology, in particular, to a compound pharmaceutical composition for treating skin inflammatory diseases, which is characterized in that an active ingredient of the compound pharmaceutical of the disclosure is composed of tofacitinib and crisaborole, and the composition has a stronger therapeutic effect and a lower dosage with a significant synergistic therapeutic effect. The pharmaceutical composition of the disclosure can be used to treat skin inflammatory diseases.

Claims

1. A pharmaceutical composition, comprising pharmaceutically active ingredients and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredients are composed of tofacitinib and crisaborole in a range of 1:8 to 8:1 weight ratio of tofacitinib:crisaborole.

2. A method for treating skin inflammatory diseases, comprising applying the pharmaceutical composition according to claim 1 to a skin.

3. The method according to claim 2, wherein the skin inflammatory diseases are allergic dermatitis, urticaria, atopic dermatitis, seborrheic dermatitis, or contact dermatitis.

4. The method according to claim 2, wherein the skin inflammatory diseases are inflammatory skin reactions caused by psoriasis or systemic lupus erythematosus.

5. The pharmaceutical composition according to claim 1, having a dosage form of an external preparation.

6. The pharmaceutical composition according to claim 5, wherein the dosage form of the external preparation is cream, gel, foam, powder, tincture, lotion, spray or patch.

7. A method for treating skin inflammatory diseases, comprising applying the pharmaceutical composition according to claim 1 to a skin.

8. The method according to claim 7, wherein the skin inflammatory diseases are allergic dermatitis, urticaria, atopic dermatitis, seborrheic dermatitis, or contact dermatitis.

9. The method according to claim 7, wherein the skin inflammatory diseases are inflammatory skin reactions caused by psoriasis or systemic lupus erythematosus.

10. The pharmaceutical composition according to claim 1, having a dosage form of an external preparation.

11. The pharmaceutical composition according to claim 10, wherein the dosage form of the external preparation is cream, gel, foam, powder, tincture, lotion, spray or patch.

Description

DESCRIPTION OF EMBODIMENTS

Embodiment 1

(1) For ointment, the prescription is as follows:

(2) TABLE-US-00002 Component Concentration (% W/W) Crisaborole 1.0% Tofacitinib 1.0% Albolene  60% Glycerin monostearate  10% Propylene glycol 19.98%  Glycerinum .sup. 8% Dibutyl hydroxytoluene 0.02% 

(3) A prescribed amount of crisaborole and Tofacitinib is taken, and dissolved or dispersed in a mixed solution of 27.98% propylene glycol and glycerin, then after they are evenly dispersed, an appropriate amount of antioxidant is added for mixing uniformly before use; another 70% white petrolatum and glycerin monostearate are taken in a stainless steel tank and heated, melted at 65° C.±5° C., then the temperature is remained, followed by slowly adding the above mixed solution into the melted matrix through mixing with a blender/homogenizer; after mixing for a period of time, the heat source is removed, and mixing is continued after cooling until completely homogeneous, so as to obtain the ointment.